Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data
- 1.4k Downloads
Practical food effect predictions and assessments were described using in silico, in vitro, and/or in vivo preclinical data to anticipate food effects and Biopharmaceutics Classification System (BCS)/Biopharmaceutics Drug Disposition Classification System (BDDCS) class across drug development stages depending on available data: (1) limited in silico and in vitro data in early discovery; (2) preclinical in vivo pharmacokinetic, absorption, and metabolism data at candidate selection; and (3) physiologically based absorption modeling using biorelevant solubility and precipitation data to quantitatively predict human food effects, oral absorption, and pharmacokinetic profiles for early clinical studies. Early food effect predictions used calculated or measured physicochemical properties to establish a preliminary BCS/BDDCS class. A rat-based preclinical BCS/BDDCS classification used rat in vivo fraction absorbed and metabolism data. Biorelevant solubility and precipitation kinetic data were generated via animal pharmacokinetic studies using advanced compartmental absorption and transit (ACAT) models or in vitro methods. Predicted human plasma concentration–time profiles and the magnitude of the food effects were compared with observed clinical data for assessment of simulation accuracy. Simulations and analyses successfully identified potential food effects across BCS/BDDCS classes 1–4 compounds with an average fold error less than 1.6 in most cases. ACAT physiological absorption models accurately predicted positive food effects in human for poorly soluble bases after oral dosage forms. Integration of solubility, precipitation time, and metabolism data allowed confident identification of a compound’s BCS/BDDCS class, its likely food effects, along with prediction of human exposure profiles under fast and fed conditions.
KEY WORDSabsorption modeling BCS/BDDCS food effect prediction human PBPK model oral bioavailability
The authors would like to thank Dr. Akash Jain and the members of the Novartis Food Effect Quality Plus team for many helpful discussions.
Conflict of Interests
- 2.US FDA. Food–effect bioavailability and fed bioequivalence studies. In: Guidance for industry. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. 2002. Accessed 02 Jun 2012.
- 8.Benet L. Z. WCY. Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities. Somerset, NJ: NJDMDG. 2006.Google Scholar
- 16.Russell WMS, Burch RL. The principles of humane experimental technique. London: Methuen & Co. Special edition published by Universities Federation for Animal Welfare (UFAW), 1992; 1959.Google Scholar
- 20.Vieira MLT, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther. 2012;91(4):700–8. doi: 10.1038/clpt.2011.305.PubMedCrossRefGoogle Scholar
- 22.Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm. 2011;79(2):349–56. doi: 10.1016/j.ejpb.2011.04.005.PubMedCrossRefGoogle Scholar
- 23.Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73(1):107–14. doi: 10.1016/j.ejpb.2009.05.009.PubMedCrossRefGoogle Scholar
- 28.Kuentz M, Nick S, Parrott N, Rothlisberger D. A strategy for preclinical formulation development using GastroPlus (TM) as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006;27(1):91–9. doi: 10.1016/j.ejps.2005.08.011.PubMedCrossRefGoogle Scholar
- 36.De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos. 2007;35(4):649–59. doi: 10.1124/dmd.106.014027.PubMedCrossRefGoogle Scholar
- 44.US FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. In: Guidance for industry. 2000. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070246.pdf. Accessed 02 Jun 2012.
- 46.Tse FLS. Pharmacokinetics in drug discovery and development: nonclinical studies. In: Welling PG, Tse FLS, editors. Pharmacokinetics: regulatory, industrial, academic perspectives. 2nd ed. New York: Dekker; 1995. p. 300–6.Google Scholar
- 47.Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011. doi: 10.1002/jps.22553.
- 48.Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci. 2011. doi: 10.1002/jps.22552.